Universitat De Les Illes Balears

Other

Rafael M Prieto Almirall

Antonia Costa Bauza

Joan Perello Bestard

Bernat Isern Amengual

Fernando Tur Espinosa

Félix Grases Freixedas

Pilar Sanchis Cortes

Isabel Gomila Muñiz

Felix Grases Freixedas

Eva Martín Becerra

Antonia Costa-Bauza

Joan Perelló Berstard

Isabel Gomila Muniz

Feliciano Grases Freixedas

Isabel Gomila MUÑOZ

Rubén HENRÍQUEZ PELÁEZ

Pilar Sanchís Cortés

This invention relates to a composition that comprises inositol phosphates and/or bisphosphonates, and to the use thereof to prevent the loss of substances of biological interest in the body of patients subjected to dialysis and to maintain sufficient physiological levels of said substances to regulate physiological and/or pathological processes, these substances being inhibitors of pathological crystallization.

Composition of dialysis liquid comprising crystallisation inhibitor substances

The invention relates to a fixed-dose association of phytate and zinc in synergic proportions for use in the treatment of crystallization of hydroxyapatite. Advantageously, said association is in a molar ratio between the phytate and the zinc exceeding 4:1. The invention also relates to the use of said association for manufacturing a drug for the treatment, prophylaxis and/or prevention crystallization of hydroxyapatite in humans.

Fixed-dose association of phytate and zinc

The invention relates to a fixed-dose association of 5 phytate and zinc in synergic proportions for use in the treatment of crystallization of hydroxyapatite. Advantageously, said association is in a molar ratio between the phytate and the zinc exceeding 4:1. The invention also relates to the use of said 10 association for manufacturing a drug for the treatment, prophylaxis and/or prevention crystallization of hydroxyapatite in humans.

Growing community of inventors

Palma De Mallorca, Spain

Rafael M Prieto Almirall